Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Copper Mining Market in Asia-Pacific to 2020Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents Expire
Forecasts from the firm’s latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a Compound Annual Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billion. As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva and Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017 respectively, a more modest increase is predicted. However, the market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact. Gilead announced Stribild's initial price as $28,500, which is one-third greater than that of Atripla, but with impressive efficacy and strong patient compliance, We do not expect this higher cost to be a significant barrier to widespread use. Last year’s sales figures show Gilead as being the greatest revenue shareholder of the world’s top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment. This report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018. For Sample Pages, please click or add the below link to your browser: http://www.globalmarketsdirect.com/ The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts. We are market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. Visit our Report Store http://www.globalmarketsdirect.com For more details contact: pressreleases@ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|